Tuberous Sclerosis Complex clinical trials

Explore recruiting tuberous sclerosis complex clinical trials.

Recruiting tuberous sclerosis complex studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tuberous Sclerosis Complex trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Treatment with full-spectrum cannabis extract of refractory epilepsy associated with Tuberous Sclerosis Complex (TSC): SPECTRUM

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of Study CRAD001M2304 (EXIST-3)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)

Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults with Seizures Associated with Tuberous Sclerosis Complex

Spain, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex

Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of RApamycin in drug Resistant Epilepsy associated with TSC

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Tuberous Sclerosis Complex trials by city

Tuberous Sclerosis Complex in Toronto Tuberous Sclerosis Complex in Vancouver Tuberous Sclerosis Complex in Montreal Tuberous Sclerosis Complex in Calgary Tuberous Sclerosis Complex in Edmonton Tuberous Sclerosis Complex in Ottawa Tuberous Sclerosis Complex in Winnipeg Tuberous Sclerosis Complex in Quebec City Tuberous Sclerosis Complex in Hamilton Tuberous Sclerosis Complex in Kitchener Tuberous Sclerosis Complex in London Tuberous Sclerosis Complex in Halifax Tuberous Sclerosis Complex in New York Tuberous Sclerosis Complex in Los Angeles Tuberous Sclerosis Complex in Chicago Tuberous Sclerosis Complex in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease